Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489028 | 0.83 | L3MBTL1 (0.47) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7068553 | 0.82 | MEN1 (0.45) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7068552 | 0.82 | KMT2A (0.43) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL7135143 | 0.82 | SMN1; SMN2 (0.48) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6501155 | 0.82 | L3MBTL1 (0.42) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6496310 | 0.70 | THRB (0.41) | KMT2AMEN1NPSR1L3MBTL1 | |
| SCHEMBL6492750 | 0.69 | KDM4E (0.43) | KMT2AMEN1NPSR1ALDH1A1LMNA | |
| SCHEMBL10265009 | 0.69 | CA1 (0.53) | KMT2AMEN1CYP3A4ALDH1A1LMNA | |
| SCHEMBL28336927 | 0.68 | MEN1 (0.53) | KMT2AMEN1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL6430006 | 0.67 | KMT2A (0.47) | KMT2AMEN1CYP1A2CYP2C19SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| WO-2004108686-A2 | BENZIMIDAZOLE COMPOUNDS HAVING HYPOGLYCEMIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | KMT2A 561/4885MEN1 1604/4885CYP1A2 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.